{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:24:21Z","timestamp":1792740261386,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":1772,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1038\/mt.2011.179","type":"journal-article","created":{"date-parts":[[2011,8,30]],"date-time":"2011-08-30T14:28:01Z","timestamp":1314714481000},"page":"2239-2248","source":"Crossref","is-referenced-by-count":43,"title":["Combining mTor Inhibitors With Rapamycin-resistant T Cells: A Two-pronged Approach to Tumor Elimination"],"prefix":"10.1016","volume":"19","author":[{"given":"Leslie E","family":"Huye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yozo","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuri P","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Yvon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Savoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpietro","family":"Dotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona M","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2011.179_bib1","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J Exp Med"},{"key":"10.1038\/mt.2011.179_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm0596-551","article-title":"Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes","volume":"2","author":"Heslop","year":"1996","journal-title":"Nat Med"},{"key":"10.1038\/mt.2011.179_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"10.1038\/mt.2011.179_bib4","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"10.1038\/mt.2011.179_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3816\/CLM.2006.n.011","article-title":"Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma","volume":"6","author":"Bollard","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1038\/mt.2011.179_bib6","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"key":"10.1038\/mt.2011.179_bib7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.coi.2009.03.002","article-title":"Adoptive cell therapy for the treatment of patients with metastatic melanoma","volume":"21","author":"Rosenberg","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1038\/mt.2011.179_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1038\/mt.2011.179_bib9","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1089\/hum.2009.142","article-title":"Fifteen years of gene therapy based on chimeric antigen receptors: \u201care we nearly there yet?\u201d","volume":"20","author":"Dotti","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2011.179_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.coi.2010.12.005","article-title":"Strategies to counteract MHC-I defects in tumors","volume":"23","author":"Lampen","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1038\/mt.2011.179_bib11","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"10.1038\/mt.2011.179_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.immunol.25.022106.141527","article-title":"Improving T cell therapy for cancer","volume":"25","author":"Leen","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1038\/mt.2011.179_bib13","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/0008-5472.CAN-07-6286","article-title":"Targeting AKT signaling sensitizes cancer to cellular immunotherapy","volume":"68","author":"H\u00e4hnel","year":"2008","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2011.179_bib14","doi-asserted-by":"crossref","first-page":"16383","DOI":"10.1074\/jbc.M411377200","article-title":"Disruption of Mcl-1.Bim complex in granzyme B-mediated mitochondrial apoptosis","volume":"280","author":"Han","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2011.179_bib15","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood-2004-08-3337","article-title":"Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis","volume":"105","author":"Dotti","year":"2005","journal-title":"Blood"},{"key":"10.1038\/mt.2011.179_bib16","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","article-title":"Adapting a transforming growth factor \u03b2-related tumor protection strategy to enhance antitumor immunity","volume":"99","author":"Bollard","year":"2002","journal-title":"Blood"},{"key":"10.1038\/mt.2011.179_bib17","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/mt.2009.34","article-title":"Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7","volume":"17","author":"Vera","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2011.179_bib18","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/mt.2010.185","article-title":"T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms","volume":"18","author":"Sun","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2011.179_bib19","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.4049\/jimmunol.167.11.6356","article-title":"Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity","volume":"167","author":"Liu","year":"2001","journal-title":"J Immunol"},{"key":"10.1038\/mt.2011.179_bib20","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.4049\/jimmunol.175.11.7226","article-title":"Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine","volume":"175","author":"Hsu","year":"2005","journal-title":"J Immunol"},{"key":"10.1038\/mt.2011.179_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drup.2008.03.001","article-title":"Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment","volume":"11","author":"Jiang","year":"2008","journal-title":"Drug Resist Updat"},{"key":"10.1038\/mt.2011.179_bib22","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0804821105","article-title":"mTORC1 promotes survival through translational control of Mcl-1","volume":"105","author":"Mills","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2011.179_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat Med"},{"key":"10.1038\/mt.2011.179_bib24","first-page":"4472","article-title":"Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas","volume":"63","author":"Nepomuceno","year":"2003","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2011.179_bib25","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2002-01-0109","article-title":"BCR\/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1\u03b1, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin","volume":"100","author":"Mayerhofer","year":"2002","journal-title":"Blood"},{"key":"10.1038\/mt.2011.179_bib26","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","article-title":"mTOR and cancer therapy","volume":"25","author":"Easton","year":"2006","journal-title":"Oncogene"},{"key":"10.1038\/mt.2011.179_bib27","doi-asserted-by":"crossref","first-page":"45643","DOI":"10.1074\/jbc.M404097200","article-title":"Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1\u03b1, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase\/AKT signaling","volume":"279","author":"Skinner","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2011.179_bib28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/onc.2008.384","article-title":"PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer","volume":"28","author":"Crane","year":"2009","journal-title":"Oncogene"},{"key":"10.1038\/mt.2011.179_bib29","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/CJI.0b013e3181ad762b","article-title":"Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes","volume":"32","author":"Nakazawa","year":"2009","journal-title":"J Immunother"},{"key":"10.1038\/mt.2011.179_bib30","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/mt.2011.179_bib31","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1073\/pnas.92.11.4947","article-title":"Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue","volume":"92","author":"Chen","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2011.179_bib32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/CJI.0b013e3181a8efe6","article-title":"Honokiol-mediated inhibition of PI3K\/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function","volume":"32","author":"Crane","year":"2009","journal-title":"J Immunother"},{"key":"10.1038\/mt.2011.179_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1084\/jem.20042020","article-title":"The Pim kinases control rapamycin-resistant T cell survival and activation","volume":"201","author":"Fox","year":"2005","journal-title":"J Exp Med"},{"key":"10.1038\/mt.2011.179_bib34","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2011.179_bib35","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.4049\/jimmunol.0903805","article-title":"Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice","volume":"186","author":"Wang","year":"2011","journal-title":"J Immunol"},{"key":"10.1038\/mt.2011.179_bib36","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/mt.sj.6300134","article-title":"Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules","volume":"15","author":"Suhoski","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2011.179_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.mt.6300028","article-title":"PiggyBac transposon-mediated gene transfer in human cells","volume":"15","author":"Wilson","year":"2007","journal-title":"Mol Ther"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616327095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616327095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T21:35:32Z","timestamp":1592861732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616327095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1525001616327095"],"URL":"https:\/\/doi.org\/10.1038\/mt.2011.179","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}